YERVOY[®] (ipilimumab)

Patient Alert Card

 This card has important information on the use of ipilimumab.

 This document is approved by The Executive Directorate of Pharmacovigilance, at SFDA.

June 2020

731AE2006063-03

H Bristol Myers Squibb

Bristol Myers Squibb,Saudi Arabia: 4t: medinfo.saudiarabia@bms.com or call: 800 844 7710 The national Pharmacovigilance

> For reporting any suspected adverse reactions via the national reporting system :

The national Pharmacovigilance and Drug safety Center : thtps://ade.sfda.gov.sa/Home/Report mail: npc.drug@sfda.gov.sa Toll free number: 19999

731AE2006063-03

Myers Squibb

USUS anu

Important Information for Patients

Please carry this card with you at all times to inform healthcare professionals that you are receiving treatment with YERVOY[®] alone.

If you have any signs or symptoms, tell your doctor right away.

POSSIBLE SIDE EFFECTS

BOWEL AND STOMACH

- diarrhea (watery, loose or soft stools), redness in the eye. bloody or dark-colored stools.
- more frequent bowel movements than usual.
- pain or tenderness in your stomach or abdomen area, nausea, vomiting.

LIVER

- eye or skin yellowing (jaundice).
- pain on the right side of your stomach area.
- dark urine.

山 SKIN

- skin rash with or without itching, dry skin.
- blisters and/or peeling of the skin, mouth sores.
- swelling of the face or lymph glands.

EYE

- pain in the eye.
- vision problems or blurry vision.

NERVE

- muscle weakness.
- numbness or tingling in legs, arms or face.
- dizziness, loss of consciousness or difficulty waking up.

GENERAL

- fever, headache, tiredness.
- bleeding.
- behavioral changes (e.g. less sex drive, being irritable or forgetful).
- dehydration, low blood pressure, shock.

IMPORTANT

- Tell your doctor of any previous medical conditions, including if you have had a stem cell transplant that uses donor stem cells (allogeneic).
- Early treatment of side effects reduces the likelihood that YERVOY[®] treatment will need to be temporarily or permanently stopped.
- Signs and symptoms that may appear mild can guickly worsen if left untreated.
- DO NOT try to treat these symptoms yourself.
- Signs and symptoms may be delayed and may occur weeks to months after your last YERVOY[®] injection.

June 2020

731AE2006063-03

My Doctor's Contact Information (who prescribed YERVOY[®])

Name of Doctor:

Office Phone:

After-Hours Phone:

My Contact Information

My Name and Phone:

Caregiver Name and Phone (in case of emergency):

i IMPORTANT Information for Healthcare Professionals

- This patient is treated with **YERVOY**[®] monotherapy.
- Immune-related adverse reactions (irARs) may appear at any time during treatment or months after its discontinuation.
- Early diagnosis and appropriate management are essential to minimize life-threatening complications.
- Consultation with an oncologist or other medical specialist may be helpful for management of organ-specific irARs.
- Healthcare professionals should refer to the YERVOY[®] Prescribing Information which can be found in the product pack.

The healthcare professional treating this patient with YERVOY[®] should complete the 'My Doctor's Contact Information' section of this Patient Alert Card.

June 2020

731AE2006063-03